Authors
[:fr]Francesco Puleo[:],
[:fr]Jeremy Augustin[:],
[:fr]Jean-Francois Emile[:],
[:fr]Magali Svrcek[:],
[:fr]Tatjana Arsenijevic[:],
[:fr]Jean-Luc Van Laethem[:],
[:fr]Jean-Baptiste Bachet[:],
Abstract
Background
Few patients with pancreatic adenocarcinoma (PAC) are eligible for surgery. Patients with early relapse have a poor prognosis and might be better candidates for a medical approach. Clinical and pathological parameters only partially predict recurrence and are only obtained after surgery. PAC subtypes based on gene expression were proposed, and we assessed if they could predict the risk and type of recurrence independently of clinicopathological parameters.
Methods
Patients with curative-intent surgery for PAC without pretreatment were selected and divided into two independent cohorts defined as discovery (n = 381) and validation (n = 149) cohorts. Transcriptomic analyses were performed on formalin-fixed paraffin-embedded surgical samples to characterise tumour and stroma compartments using previously defined signatures. We associated molecular and clinicopathological characteristics with general, distant, and local recurrences using Cox regression analyses.
Results
We found that tumour biology predicted distant recurrence contrary to local recurrence, which was directly related to resection margin status. Pure basal-like and stroma-activated subtypes were strongly associated with distant recurrence, independently of clinicopathological factors (hazard ratios [HRs] = 5.85, p < 0.001 and HR = 1.75, p = 0.007, respectively). By dissecting tumoural and stromal compartments, we demonstrated that the basal-like tumour component positively correlated with distant recurrence in both cohorts (HR = 1.45, p < 0.001 and HR = 1.90, p < 0.001), whereas the inactive structural stroma component was protective against distant recurrence (HR = 0.68, p < 0.001 and HR = 0.72, p < 0.001).
Conclusions
In addition to suggesting a different mechanism for local and distant relapse (incomplete resection and high metastatic potential, respectively), our results show the potency of molecular phenotype to predict patient outcome regarding distant recurrences.
Other publications
05 Jan 2022
Authors :
[:fr]C. Saillard[:],
[:fr]F. Delecourt[:],
[:fr]B. Schmauch[:],
[:fr]O. Moindrot[:],
[:fr]M. Svrcek[:],
[:fr]A. Bardier-Dupas[:],
[:fr]J-F. Emile[:],
[:fr]M. Ayadi[:],
[:fr]V. Rebours[:],
[:fr]L. de Mestier[:],
[:fr]P. Hammel[:],
[:fr]C. Neuzillet[:],
[:fr]J-B. Bachet[:],
[:fr]J. Iovanna[:],
[:fr]N. Dusetti[:],
[:fr]Y. Blum[:],
[:fr]M. Richard[:],
[:fr]Y. Kermezli[:],
Paradis Valérie,
[:fr]M. Zaslavskiy[:],
[:fr]P. Courtiol[:],
[:fr]A. Kamoun[:],
Nicolle Rémy,
Cros Jérome,
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma
[:fr]Annals of Oncology.[:]
11 Nov 2020
Authors :
Nicolle Rémy,
[:fr]O. Gayet[:],
[:fr]P. Duconseil[:],
[:fr]C. Vanbrugghe[:],
[:fr]J. Roques[:],
[:fr]M. Bigonnet[:],
[:fr]Y. Blum[:],
[:fr]N. Elarouci[:],
[:fr]L. Armenoult[:],
[:fr]M. Ayadi[:],
[:fr]A. de Reyniès[:],
[:fr]F. Puleo[:],
[:fr]J. Augustin[:],
[:fr]J.F. Emile[:],
[:fr]M. Svrcek[:],
[:fr]T. Arsenijevic[:],
[:fr]P. Hammel[:],
[:fr]M. Giovannini[:],
[:fr]P. Grandval[:],
[:fr]L. Dahan[:],
[:fr]V. Moutardier[:],
[:fr]M. Gilabert[:],
[:fr]J.L. Van Laethem[:],
[:fr]J.B. Bachet[:],
Cros Jérome,
[:fr]J. Iovanna[:],
[:fr]N.J. Dusetti[:],
03 Jul 2020
Authors :
Nicolle Rémy,
[:en]Yuna Blum[:],
[:en]Pauline Duconseil[:],
[:en]Charles Vanbrugghe[:],
[:en]Nicolas Brandone[:],
[:en]Flora Poizat[:],
[:en]Julie Roques[:],
[:en]Martin Bigonnet[:],
[:en]Odile Gayet[:],
[:en]Marion Rubis[:],
[:en]Nabila Elarouci[:],
[:en]Lucile Armenoult[:],
[:en]Mira Ayadi[:],
[:en]Aurélien de Reyniès[:],
[:en]Marc Giovannini[:],
[:en]Philippe Grandval[:],
[:en]Stephane Garcia[:],
[:en]Cindy Canivet[:],
Cros Jérome,
[:en]Barbara Bournet[:],
[:en]Louis Buscail[:],
[:en]BACAP Consortium[:],
[:en]Vincent Moutardier[:],
[:en]Marine Gilabert[:],
[:en]Juan Iovanna[:],
[:en]Nelson Dusetti[:],